LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

PerkinElmer Inc

Fechado

SetorSaúde

0

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

Indicadores-chave

By Trading Economics

Rendimento

-8.6M

47M

Vendas

-21M

699M

P/E

Médio do Setor

52.799

80.03

EPS

1.18

Rendimento de Dividendos

0.27

Margem de lucro

6.675

Funcionários

11,000

EBITDA

-14M

181M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+8.46% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.27%

2.29%

Próxima data de ex-dividendo

16 de jan. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

612M

12B

Abertura anterior

0

Fecho anterior

0

PerkinElmer Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de dez. de 2025, 23:21 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 de dez. de 2025, 23:14 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 de dez. de 2025, 22:01 UTC

Grandes Movimentos do Mercado

Costco Wholesale Reports Higher Monthly Sales

3 de dez. de 2025, 21:38 UTC

Ganhos

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 de dez. de 2025, 23:59 UTC

Conversa de Mercado

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 de dez. de 2025, 23:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de dez. de 2025, 23:49 UTC

Conversa de Mercado

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 de dez. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 de dez. de 2025, 23:13 UTC

Conversa de Mercado

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 de dez. de 2025, 23:10 UTC

Ganhos

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 de dez. de 2025, 23:08 UTC

Conversa de Mercado

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 de dez. de 2025, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 de dez. de 2025, 22:59 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB to Buy PC Financial From Loblaw for About $573.5M

3 de dez. de 2025, 22:45 UTC

Conversa de Mercado

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 de dez. de 2025, 22:20 UTC

Ganhos

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 de dez. de 2025, 22:19 UTC

Ganhos

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 de dez. de 2025, 22:17 UTC

Ganhos

Salesforce Working to Add Voice to Agentforce, CEO Says

3 de dez. de 2025, 22:16 UTC

Ganhos

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 de dez. de 2025, 22:15 UTC

Ganhos

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 de dez. de 2025, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 de dez. de 2025, 22:09 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

3 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

3 de dez. de 2025, 21:49 UTC

Ganhos

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 de dez. de 2025, 21:23 UTC

Ganhos

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 de dez. de 2025, 21:19 UTC

Ganhos

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 de dez. de 2025, 21:06 UTC

Ganhos

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 de dez. de 2025, 21:04 UTC

Ganhos

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 de dez. de 2025, 21:04 UTC

Ganhos

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 de dez. de 2025, 21:03 UTC

Ganhos

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparação entre Pares

Variação de preço

PerkinElmer Inc Previsão

Preço-alvo

By TipRanks

8.46% parte superior

Previsão para 12 meses

Média 111.1 USD  8.46%

Máximo 125 USD

Mínimo 100 USD

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para PerkinElmer Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

8

Comprar

3

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat